Product label
Approved product label
Adults with HIV-associated lipodystrophy and excess abdominal fat; not general weight loss.
Reported findings. Adults with HIV-associated lipodystrophy and excess abdominal fat; not general weight loss. Egrifta WR, for its labeled HIV-associated indication.
Nonresponse. Responses vary; no population guarantee.
Harms. Elevated IGF-1, glucose intolerance and fluid retention are label warnings.
Limits. Labeled preparation only; marketed variants do not inherit approval.
Preparation: Egrifta WR, for its labeled HIV-associated indication. Route: subcutaneous WR, not substitutable with SV
Read original source ↗Editorial review 2026-10-09. Clinician review pending.